Article

Verteporfin developer honored for research

Vancouver, British Columbia-A research chemist from QLT Inc. who helped develop the verteporfin for injection (Visudyne, QLT/Novartis Ophthalmics) treatment for age-related macular degeneration is among 13 chemists from four companies who have been named Heroes of Chemistry by the American Chemical Society.

Vancouver, British Columbia-A research chemist from QLT Inc. who helped develop the verteporfin for injection (Visudyne, QLT/Novartis Ophthalmics) treatment for age-related macular degeneration is among 13 chemists from four companies who have been named Heroes of Chemistry by the American Chemical Society.

David H. Dolphin, PhD, and other honorees received their awards Aug. 22 at the society's 228th national meeting in Philadelphia. He is vice president, technology development at QLT Inc. and professor of chemistry and the QLT/NSERC Industrial Research Professor in Photodynamic Technologies at the University of British Columbia (UBC) in Vancouver, Canada. Dr. Dolphin received his doctorate in chemistry from the University of Nottingham, England, in 1965.

"The chemical advances made by our 'heroes' serve as testimonials to the valuable role chemists, chemical engineers, and allied scientists play in improving lives," said Charles P. Casey, PhD, the society's president.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
(Image credit: Ophthalmology Times) ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
(Image credit: Ophthalmology Times) Oluwatosin U. Smith talks Glaukomtecken
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
(Image credit: Ophthalmology Times) NeuroOp Guru: Cranial nerve six palsy with chemosis is a critical clue to cavernous carotid fistula
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
© 2025 MJH Life Sciences

All rights reserved.